RCEL - AVITA Medical Inc
IEX Last Trade
9.37
0.260 2.775%
Share volume: 100,098
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.11
0.26
2.85%
Fundamental analysis
25%
Profitability
25%
Dept financing
9%
Liquidity
75%
Performance
17%
Performance
5 Days
0.21%
1 Month
-5.93%
3 Months
0.65%
6 Months
-44.52%
1 Year
-43.03%
2 Year
47.63%
Key data
Stock price
$9.37
DAY RANGE
N/A - N/A
52 WEEK RANGE
$7.51 - $18.93
52 WEEK CHANGE
-$0.43
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Michael Perry
Region: US
Website: http://www.avitamedical.com/
Employees: 154
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.avitamedical.com/
Employees: 154
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.
Recent news